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BACKGROUND: The germline BRCA2 mutation is associated with increased prostate cancer (PrCa) risk. We have assessed survival
in young PrCa cases with a germline mutation in BRCA2 and investigated loss of heterozygosity at BRCA2 in their tumours.
METHODS: Two cohorts were compared: one was a group with young-onset PrCa, tested for germline BRCA2 mutations (6 of 263
cases had a germline BRAC2 mutation), and the second was a validation set consisting of a clinical set from Manchester of known
BRCA2 mutuation carriers (15 cases) with PrCa. Survival data were compared with a control series of patients in a single clinic as
determined by Kaplan–Meier estimates. Loss of heterozygosity was tested for in the DNA of tumour tissue of the young-onset group
by typing four microsatellite markers that flanked the BRCA2 gene, followed by sequencing.
RESULTS: Median survival of all PrCa cases with a germline BRCA2 mutation was shorter at 4.8 years than was survival in controls at
8.5 years (P¼0.002). Loss of heterozygosity was found in the majority of tumours of BRCA2 mutation carriers. Multivariate analysis
confirmed that the poorer survival of PrCa in BRCA2 mutation carriers is associated with the germline BRCA2 mutation per se.
CONCLUSION: BRCA2 germline mutation is an independent prognostic factor for survival in PrCa. Such patients should not be managed
with active surveillance as they have more aggressive disease.
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Prostate cancer (PrCa) is a significant public health problem. In
the European Union, approximately 200000 men are diagnosed
annually with the disease. There are 35515 cases (Cancer Research
UK, 2009a) per year in the United Kingdom and 10239 deaths
(Cancer Research UK, 2009b). It is now the commonest male non-
cutaneous cancer diagnosed in the United Kingdom; the lifetime
risk of being diagnosed with PrCa is 1 in 10 (Cancer Research UK,
2009a). Although the increase in population screening is leading
to an increase in diagnosis, many men will not develop aggressive
disease. However, it is recognised that some PrCa cases have
a particularly poor prognosis. Although there are some histo-
logical and stage predictors of prognosis (Kattan and Scardino,
2002), until recently, none of them have been related to inherited
factors.
Multiple aetiologies have been proposed to contribute to the
development of PrCa. There is strong evidence that inherited
genetic factors are important and exhibit significant familial
aggregation in some men, particularly when affected at a young age
(Woolf, 1960; Edwards and Eeles, 2004). There is a recognised
association of breast cancer with PrCa in families (Thiessen, 1974;
Anderson and Badzioch, 1992; Tulinius et al, 1992). Male relatives
in breast cancer families in Iceland have a 2–3-fold risk of PrCa
(Sigurdsson et al, 1997). The breast cancer predisposition genes
BRCA1 and BRCA2 have been reported to increase the risk of
PrCa by three-fold and seven-fold, respectively, in male mutation
carriers ascertained through a family history of breast cancer
(Ford et al, 1994; Struewing et al, 1997; Breast Cancer Linkage
Consortium, 1999). Analyses of PrCa relative risks (RR) in male
mutation carriers in breast cancer families from the Breast Cancer
Linkage Consortium showed an RR of 4.65 (95% CI: 3.48–6.22) of
PrCa in male BRCA2 mutation carriers (the RR is 7.33 below the
age of 65 years) and of 1.07 (0.75–1.54) in BRCA1 carriers (with an
RR of 1.82 (1.01–3.29) for men under 65 years of age) (Thompson
and Easton, 2001, 2002). The estimated cumulative incidence
of PrCa by the age of 70 years is 7.5–33%. Recent studies have
suggested that the risk of PrCa in BRCA2 mutation carriers may
be as high as an RR of 23-fold at age 60 years (Edwards et al,
2003). Studies from Iceland have reported that germline muta-
tions in BRCA2 may be involved not only in susceptibility to
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sPrCa but also in the aggressiveness of the disease (Sigurdsson
et al, 1997; Tryggvadottir et al, 2007). However, these individuals
all carried a common founder mutation (999del5 in BRCA2).
Narod et al (2008) have reported that PrCa survival in BRCA2
mutation carriers is much shorter (median survival from diagnosis
was 4 years) when compared with BRCA1 carriers’ survival
(median survival from diagnosis was 8 years). In PrCa, in
which the BRCA2 germline mutation status was unknown, allele
loss at the BRCA2 locus has been shown to be a prognostic factor
for survival on univariate analysis (Edwards et al, 1998), and
loss of the wild-type allele would imply a tumour suppressor
mechanism in predisposition to this disease in BRCA2 mutation
carriers, but it is not known whether this is a surrogate for high
grade or is due to mutation per se (Knudson, 1971; Willems et al,
2008).
A BRCA2 genomic screening study has previously been under-
taken by ourselves, and six potentially pathogenic germline BRCA2
mutations were found in a set of 263 PrCa patients diagnosed
at p55 years (2.3%) (Edwards et al, 2003). In this study we report
clinical follow-up data and the results of loss of heterozygosity
(LOH) analyses on PrCa tumours from the mutation carriers in
this report.
We then studied a second validation data set of men with
germline mutations in the BRCA2 gene from a cancer genetics
clinic and assessed their survival to confirm our results in a
different UK data set of male BRCA2 mutation carriers with PrCa.
MATERIALS AND METHODS
Patient recruitment and survival analyses
Two groups of men with PrCa were studied.
1) A series of men with PrCa from the UK Genetic Prostate
Cancer Study (UKGPCS):
Patient recruitment was conducted as reported in a previous
article (Eeles et al, 1997). The coding region of BRCA2 was
analysed from blood DNA from 263 PrCa patients diagnosed at
p55 years and germline mutations in BRCA2 were found in 6 men
(2.3%) (Edwards et al, 2003). The control group consisted of men
from a systematic series of prostate cancer patients, age and stage
matched from our prostate cancer clinic (1587 cases). The majority
of patients had clinically presenting (non-screen detected) disease
at diagnosis. Clinical data were collected on survival/date of last
follow-up for both deleterious BRCA2 mutation carriers and
controls. Supplementary Table 1 shows the demographic and
clinical characteristics of prostate cancer in this group of patients,
for both the cases and controls.
2) Men with PrCa who also harbour a germline BRCA2 mutation
from a clinical series:
Men attending a cancer genetics clinic in Manchester, who were
found on clinical genetic testing to harbour BRCA2 mutations,
were reviewed from the Access clinical database and their date of
death or last follow-up was ascertained from the cancer registry or
from their clinical notes.
Written informed consent was obtained from individuals in this
study (ethics number 06/MRE02/4).
Overall survival was measured from date of diagnosis to date of
death or last follow-up. Kaplan–Meier survival analyses were
undertaken with patients censored at date of last follow-up. The
overall survival of those with and without germline mutations in
BRCA2 in group 1 was compared using the log-rank test. The
overall survival for those in group 2 was also calculated separately
and in combination with group 1. The effect of other factors that
could affect survival was analysed using Cox regression. The
factors investigated were stage at diagnosis, incidental PSA
detection, Gleason score, grade, whether they had a prostatectomy,
PSA at diagnosis and age.
DNA extraction and LOH studies
Germline DNA was obtained from peripheral blood samples and
extracted as reported in previous articles (Edwards et al, 1997).
Tumour DNA was obtained from microdissected formalin-fixed
paraffin-embedded (FFPE) blocks and extracted as reported in
previous articles (Edwards et al, 1998). Normal tissue DNA was
also obtained in the same way.
Four microsatellite markers, D13S260, D13S171, D13S267 and
D13S1493 within and flanking the BRCA2 gene, were typed on
five tumours from those men in group 1 using an ABI (Applied
Biosystems, Life Technologies Corporation, Carlsbad, CA, USA)
377 Genetic Analyser. The ‘peak height’ of the alleles was used to
determine the ratio of allelic loss compared with either genomic
DNA or adjacent normal tissue from paraffin blocks. Percentage
allele loss for informative markers (minimum of two) was averaged
for each patient.
To determine which allele was lost in the microsatellite LOH
results, a sequencing method was used as described in Boettger
et al (2003). We used Applied Biosystems dRhodamine chemistry
on a 377 Genetic Analyser (Edwards et al, 2003). An average value
for the loss was estimated by examining a number of electro-
pherogram peak height signals in the area of the mutation.
RESULTS
Survival analysis
The median overall survival of all BRCA2 mutation carriers was
significantly shorter at 4.8 years compared with that of non-
carriers at 8.5 years; log rank P¼0.003 (hazard ratio 2.14 (95% CI:
1.28–3.56); see Figure 1). When analysed by method of ascertain-
ment (see methods), the median survival of the six BRCA2 carriers
in group 1 was significantly shorter at 3.6 years (P¼0.002; hazard
ratio 3.36 (95% CI: 1.50–7.50)), when compared with that of
non-carriers. In group 2, the 15 men with germline BRCA2
mutations and PrCa had a median survival of only 5.0 years.
The mutations in BRCA2 in the men with PrCa are listed in
Table 1.
Table 2 shows the univariate results. This shows that the
following factors are associated with a poorer overall survival:
germline BRCA2 mutation status, tumour (T), nodal (N) and
metastasis (M) stage, tumour detected clinically rather than
by PSA screening, higher Gleason score, treatment that did not
involve prostatectomy, PSA at diagnosis of X25ngml
 1 and age
455 years at diagnosis. In a multivariate analysis, which is shown
in Table 3, germline BRCA2 mutation status, T and nodal (N)
tumour stage, higher grade, treatment that did not involve
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Figure 1 Kaplan–Meier survival estimates of 21 BRCA2 mutation carriers.
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 1 and higher age at
diagnosis remained independent prognostic factors.
Loss of heterozygosity (LOH) results
The DNA from microdissected FFPE tumour tissue was avail-
able from 5 of 6 germline BRCA2 carriers. All five showed LOH
(see Table 4). A representative microsatellite trace is shown
in Figure 2.
To estimate which allele was lost, a sequencing method was
adopted. Of the five tumour samples sequenced, it was observed
that patient F had lost the mutant allele, whereas patients A, D and
E lost the wild-type allele. The tumour from patient B had lost the
mutant allele at a low level (approx 10%; Table 4). Representative
sequence traces are shown in Figure 3.
DISCUSSION
We have shown that men with PrCa, who also harbour a
deleterious germline mutation in the BRCA2 gene, have a poorer
overall survival. This has been shown in a small sample of men
who were diagnosed at p55 years with PrCa, compared with those
diagnosed at a similarly young age, but who did not harbour a
germline mutation as determined by coding sequence analysis
from a previous study, and also men from a systematic series of
prostate cancer cases in one centre: group 1 (Edwards et al, 2003).
We have validated this in a separate data set of men who have had
PrCa at any age and who have been found to have a germline
mutation in BRCA2 by a clinical genetic testing service, in which
genetic testing was offered as part of genetic counselling of families
with mutations: group 2. These are usually men within breast
cancer families in which women have initially been tested to
determine the cause of familial breast cancer clustering within the
family. Again, they have a poorer prognosis than men who do not
harbour a germline BRCA2 mutation.
It has been shown that local extent or T stage, N stage and
presence or not of M stage and higher PSA at presentation are all
predictors of poorer survival (Kattan and Scardino, 2002). It was
therefore very important to determine whether the poorer survival
associated with the presence of a germline BRCA2 mutation was
independent. The multivariate analysis confirms that the presence
of a germline BRCA2 mutation is a marker of poorer overall
survival per se.
This has implications for the detection and management of men
with PrCa who are found to harbour germline mutations in the
BRCA2 gene, as their poorer survival would be a contraindication
for active surveillance. It is not yet known whether these men
Table 1 List of germline mutations in BRCA2 men with prostate cancer from group 1 (diagnosed at age 55 years or under) and group 2
Patient ID
Age at diagnosis
(Years)
BRCA2 mutation
(nt) U43746
BRCA2 mutation
(nt) NM_000059.1 Codon U43746
Codon NM_000059.1
with HGVS nomenclature
Group 1 patient A 44 8205-1g4c (IVS17-1g4c) 7977-1g4c IVS17-1 g4c (splice site) 7977-1g4c (splice site)
Group 1 patient B 47 7084delAAAAG 6856delAAAAG Stop 2291 Arg2287LeufsX4
Group 1 patient C 48 2558insA or 2558dupA 2330insA or 2330dupA Stop 787 Asp777GlufsX11
Group 1 patient D 52 8525delC 8297delC Stop 2776 Thr2766AsnfsX11
Group 1 patient E 52 6714delACAA* 6486delACAA Stop 2166 Lys2162AsnfsX5
Group 1 patient F 53 7771insA or 7771dupA 7543insA or 7543dupA Stop 2537 Thr2515AsnfsX24
Group 2 patient 1 66 6174delT 5946delT Stop 2003 Ser1982ArgfsX22
Group 2 Patient 2 66 5910C4G 5682C4G Y1894X (Tyr to Stop) Tyr1894X
Group 2 patient 3 79 9610C4T 9382C4T R3128X (Arg to Stop) Arg3128X
Group 2 patient 4 74 860-1g4a 632-1g4a IVS7-1g4a (splice site) 632-1g4a (splice site)
Group 2 patient 5 46 6503delTT (+) 10204A4T 6275-6276delTT (+) 9976A4T Stop 2098 + K3326X Leu2092ProfsX7 + Lys3326X
Group 2 patient 6 77 2157delG 1929delG Stop 659 Arg645GluX15
Group 2 patient 7 74 6503delTT (+) 10204A4T 6275-6276delTT (+) 9976A4T Stop 2098 + K3326X Leu2092ProfsX7 + Lys3326X
Group 2 patient 8 57 6819delTG 6591delTG Stop 2201 Glu2198AsnfsX4
Group 2 patient 9 59 3036delACAA 2808delACAA Stop 959 Ala938ProfsX21
Group 2 patient 10 72 6137C4A 5909C4A S1970X Ser1970X
Group 2 patient 11 62 2117delC 1889delC Stop 643 Thr630AsnfsX14
Group 2 patient 12 74 del exons 14-16 94189-?_97257+?del Del exons 14-16 del exons14_16
Group 2 patient 13 66 del exons 14-16 94189-?_97257+?del Del exons 14-16 del exons14_16
Group 2 patient 14 56 5950delCT 5722delCT Stop 1909 Leu1908ArgfsX2
Group 2 patient 15 73 2157delG 1929delG Stop 659 Arg645GluX15
Table 2 Univariate analysis of overall survival
Factor Group
Number of
patients
Hazard ratio
(95% CI) P-value
BRCA2 mutation carrier No 1587 1.00 0.003
Yes 21 2.14 (1.28–3.56)
Clinical T stage T1 165 1.00 o0.001
T2 409 1.23 (0.92–1.65)
T3 510 1.88 (1.43–2.49)
T4 152 3.87 (2.83–5.28)
TX 325 4.80 (3.63–6.36)
N stage N0 882 1.00 o0.001
N1–3 165 3.04 (2.46–3.76)
NX 514 3.32 (2.88–3.84)
M stage M0 1008 1.00 o0.001
M1 456 4.38 (3.80–5.05)
MX 86 1.61 (1.21–2.15)
Incidental PSA detection Yes 127 1.00 o0.001
No 1362 2.41 (1.74–3.34)
Gleason score p7 686 1.00 o0.001
47 181 2.30 (1.85–2.85)
Grade 1 200 1.00 o0.001
2 857 1.77 (1.38–2.27)
3 330 4.02 (3.09–5.23)
Prostatectomy Yes 82 1.00 o0.001
No 1423 4.70 (2.82–7.83)
PSA at diagnosis o25 498 1.00 o0.001
X25 487 2.19 (1.83–2.63)
Age group p55 119 1.00 0.02
455 1474 1.40 (1.05–1.87)
Age Per year 1593 1.05 (1.04–1.06) o0.001
Abbreviations: CI¼confidence interval; M¼metastasis; N¼nodal; PSA¼prostate-
specific antigen; T¼tumour.
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sshould have a particular modality of treatment (e.g., surgery rather
than radiation), as the sample sizes in this paper are too small
and treatment data are incomplete in these data sets to be able to
determine this.
Before 2008, the only data available on survival in men
with PrCa who harbour germline mutations in BRCA2 were from
Iceland, where there is a founder mutation (Thorlacius et al, 1996;
Sigurdsson et al, 1997; Tryggvadottir et al, 2007). Tryggvadottir
et al (2007) found that PrCa carriers with the BRCA2 999del5
mutation had a lower mean age at diagnosis, more advanced PrCa
as assessed by stage and grade, and a shorter median survival
time compared with non-carriers. Their study showed a median
survival time for carriers (30) of 2.1 years, which was significantly
shorter than the 12.4 years for non-carriers (497). The survival
time of the Icelandic carriers is much shorter than that reported
for our early-onset group 1 carriers of 4 years. One factor to be
noted in the Tryggvadottir et al (2007) study is that all of the 527
PrCa patients were related to breast cancer patients, 28% of whom
were first-degree relatives. Of the 527 patients, 30 were determined
to be 999del5 carriers. It is therefore possible that the poorer
prognosis that was reported could have pertained only to this
specific mutation type. This result, and its potential specificity by
virtue of mutation and population, has been discussed further by
Boormans and Schro ¨der (2007). In contrast, we have shown that
in the UK population, men with a variety of other mutations in
BRCA2, are likely to have a similarly poorer survival, and therefore
the poorer survival is likely to be related to different deleterious
mutations in the BRCA2 gene.
We found LOH in the five available PrCa tumours from men in
group 1.Three of the five tumours had lost the wild-type allele.
This is consistent with a tumour suppressor model and indicative
of a causal relationship between BRCA2 germline mutations and
predisposition to PrCa in these individuals. Loss of the mutant
allele was also observed. The implication is that for disease
causation, maybe a gene dosage effect is important.
Tommiska et al (2008) have recently proposed a model of
‘conditional haploinsufficiency’, whereby defects in genes such as
BRCA1 or BRCA2 can disrupt the regulation of other important
genome integrity monitoring genes such as ATM. In this hypothesis,
the local effects of these predisposing genes, by virtue of perhaps
increased DNA double-strand breaks, would ultimately cause ATM
protein inactivation as the cells progressed to malignancy. Although
this haploinsufficiency mechanism has only been investigated in
breast cancer, it may have implications for the development of PrCa
in the carriers that we studied, and could explain why we saw loss
of mutant alleles in comparison with the classical loss of wild type.
There is very scant literature on the ‘classical’ loss of wild-type
alleles from PrCa patients who are BRCA2 carriers. Gudmundsson
et al (1995) and Gro ¨nberg et al (2001) have reported LOH in PrCa
patients. Gudmundsson et al (1995) investigated five high-risk
breast cancer families and found seven men with PrCa, six of
whom had LOH at the BRCA2 locus. Gro ¨nberg et al (2001) studied
a breast/prostate family (three breast cancer, five PrCa) that was
found to have a deleterious BRCA2 mutation (6051delA). Of the
four brothers with PrCa, two had LOH (loss of WT) and two
retained heterozygosity.
Willems et al (2008) reported on the screening of a large series
of kConFab Australian BRCA2 breast cancer families. There were
many men with PrCa in these families; however, 20 were confirmed
to be BRCA2 carriers, and 14 of them had tumours that were
available for analysis by multiplex ligation-dependent probe
amplification (MLPA). This technique is able to assay the entire
BRCA2 gene for loss of promoter and coding regions. Of the
14 BRCA2 carriers, 10 showed loss of heterozygosity by the MLPA
method. The set comprised six men with a known family history of
PrCa and all the six showed LOH at BRCA2. The conclusion was
that the wild-type allele was most often lost, but for the four cases
that showed no LOH, epigenetic and haploinsufficiency models
were postulated as possible mechanisms. This allele determination
was assessed by a sequencing technique that is similar to the
one we used. Willems et al (2008) reported comprehensive clinical
data on their carriers and it is noteworthy that all 10 PrCa cases
presented with high Gleason scores of 9. This is a finding that
is similar to the high-grade presentation of the men in our study
Table 3 Multivariate analysis of overall survival (significant factors only)
Factor Group Number of patients Number of events Hazard ratio (95%CI) P-value
BRCA2 mutation carrier No 506 218 1 0.002
Yes 3 3 7.54 (2.11–26.98)
Clinical T stage T1 51 16 1 0.002
T2 158 49 0.99 (0.56–1.75)
T3 202 87 1.19 (0.68–2.05)
T4 50 34 1.87 (1.00–3.48)
TX 48 35 2.34 (1.24–4.40)
N stage N0 344 111 1 o0.001
N1–3 66 40 2.01 (1.36–2.98)
NX 99 70 3.72 (2.65–5.23)
Grade 1 33 7 1 o0.001
2 376 152 2.24 (1.03–4.88)
3 100 62 3.94 (1.78–8.73)
Prostatectomy Yes 31 4 1 0.044
No 478 217 2.84 (1.03–7.85)
PSA at Diagnosis o25 282 96 1 0.027
X25 227 125 1.39 (1.04–1.86)
Age Per year> 509 221 1.02 (1.00–1.04) 0.026
Abbreviations: CI¼confidence interval; N¼nodal; PSA¼prostate-specific antigen; T¼tumour.
Table 4 LOH frequencies observed for the five patients from group 1
Patient ID
Number of
informative markers LOH (%)
a Allele lost
b
A3 7 7 W T
B 4 87 MUT
D2 9 7 W T
E4 7 7 W T
F 3 81 MUT
Abbreviations: MUT¼mutant; LOH¼loss of heterozygosity; WT¼wildtype.
aLOH
(%) by microsatellite analysis (average).
bAllele loss estimation by sequencing.
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Willems et al (2008), are lower than the RR reported by us in 2003
(Edwards et al, 2003).
In 2008, Narod et al (2008) reported data on a panel of PrCa
patients with BRCA1 and BRCA2 germline mutations identified
from breast cancer families. For the combined group of known
and inferred carriers, the median survival for 183 BRCA2
patients was 4.0 years vs 8.0 years for the 119 men in the BRCA1
group. When only known carriers were analysed, the results were
5.0 years (67 BRCA2 known carriers) and 15.0 years (37 BRCA1
Microsatellite LOH
Tumour
Genomic
Patient D: D13S1493
Arrows shows LOH
100%, loss of shorter allele
Patient A: D13S1493
Arrows shows LOH
76%, loss of shorter allele
Tumour
Genomic
225 230 225
226.50 238.50
238.51 230.60 226.53 226.53
3000
2000
2000
1000
1500
1000
500
230 235 240
4000
3000
3000
2000
2000
1000
1000
230.56
Figure 2 Example of LOH seen with D13S1493 in two patients – A and D.
Patient F: 7772insA
Wild-type germline sequence
WT ‘G’ - arrowed
Heterozygote germline sequence
‘G’ signal reduced in HET – arrowed
(also position of insertion)
Tumour sequence
showing loss of MUTANT allele
as ‘G’ signal (black) is retained
similar to WT
Patient D: 8525delC
Wild-type germline sequence
WT ‘G’ - arrowed
Heterozygote germline sequence
‘G’ signal reduced in HET – arrowed
Tumour sequence
showing loss of WT allele
as ‘G’ signal (black) is lower in
tumour
Patient A IVS17–1 G>C
Wild-type germline sequence
WT ‘C’ - arrowed
Heterozygote germline sequence
‘C’ signal reduced in HET – arrowed
Tumour sequence
showing loss of WT allele
as ‘C’ signal (blue) is lower in tumour
Figure 3 Examples of allele loss in patients A, D and F. Arrows show the position of a representative peak for signal analysis.
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sknown carriers). Although there is a difference in the survival of
BRCA1 patients, which is discussed by the authors, the poorer
survival of BRCA2-related patients is not in dispute. Use of either
survival measure, 4 or 5 years, illustrates that the median survival
of the patients studied is very similar to that observed in our study
of 4.8 years.
It is not yet known whether earlier detection of PrCa in men
with germline mutations in BRCA2 will result in a better outcome
and whether PSA screening is suitable for such a population. The
IMPACT study (Identification of Men with a genetic predisposition
to ProstAte Cancer: Targeted screening in BRCA1 and BRCA2
mutation carriers and controls) has been developed to investigate
the role of targeted PrCa screening in male BRCA1 and BRCA2
gene mutation carriers using an annual PSA screen (Mitra et al,
2007). Early data have suggested that men will uptake screening
and that PrCa was twice as likely in BRCA1/2 mutation carriers
(Horsburgh et al, 2005).
Our data have shown that the observation in Iceland, which
shows that men who carry the Icelandic founder mutation in the
BRCA2 gene who also develop PrCa have a poorer survival, is not
restricted to this mutation and we have shown that this is due to
the presence of a deleterious mutation within the BRCA2 gene
per se. There is some dispute about the precise frequency of
germline BRCA2 mutation in men with PrCa. This is reported to be
about 1% in men aged p55 years in a US series (Agalliu et al,
2007), but this may be equivalent to 65–68 years at clinical
diagnosis, as the prevalence of PSA screen-detected disease is
higher in the United States. This is likely to be the case, as in this
US series, 67.3% of men had a PSA of o10. We have found that
2.3% of men diagnosed with clinically presenting disease (non-PSA
detected) have a germline BRCA2 mutation (Edwards et al, 2003).
Even if the incidence of a germline mutation in men with young-
onset (defined as p55 years at diagnosis) PrCa was as low as 2%,
the finding of a BRCA2 mutation would be an indication to avoid
active surveillance in these patients, as they have a more aggressive
disease outcome.
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